These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29851119)

  • 1. Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP.
    Cohen A; Bonini S
    Br J Clin Pharmacol; 2018 Jul; 84(7):1399-1400. PubMed ID: 29851119
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union.
    de Jong AJ; Santa-Ana-Tellez Y; van Thiel GJMW; Zuidgeest MGP; Siiskonen SJ; Mistry D; de Boer A; Gardarsdottir H;
    Clin Pharmacol Ther; 2021 Jun; 109(6):1517-1527. PubMed ID: 33666223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 5. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
    Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
    Seitz R; Enzmann H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
    [No Abstract]   [Full Text] [Related]  

  • 8. Europe must find a new home for its drug regulator - and a way to keep using English.
    Nature; 2017 Apr; 544(7648):6. PubMed ID: 28383003
    [No Abstract]   [Full Text] [Related]  

  • 9. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Registration of new medicinal products in Europe].
    Singer E
    Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.
    Ollivier C; Thomson A; Manolis E; Blake K; Karlsson KE; Knibbe CAJ; Pons G; Hemmings R
    Br J Clin Pharmacol; 2019 Apr; 85(4):659-668. PubMed ID: 30707770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A European initiative to unclog pipeline for new medicines.
    Macleod M; Steckler T
    Nature; 2019 Apr; 568(7753):458. PubMed ID: 31015692
    [No Abstract]   [Full Text] [Related]  

  • 14. The European Medicines Agency's plans for sharing data from clinical trials.
    Groves T; Godlee F
    BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
    van Gerven J; Bonelli M
    Br J Clin Pharmacol; 2018 Jul; 84(7):1401-1409. PubMed ID: 29451320
    [No Abstract]   [Full Text] [Related]  

  • 16. Fractured European market undermines biosimilar launches.
    Moran N
    Nat Biotechnol; 2008 Jan; 26(1):5-6. PubMed ID: 18183000
    [No Abstract]   [Full Text] [Related]  

  • 17. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
    Dickson R; Boland A; Duarte R; Kotas E; Woolacott N; Hodgson R; Riemsma R; Grimm S; Ramaekers B; Joore M; Büyükkaramikli N; Kaltenthaler E; Stevenson M; Pandor A; Edwards S; Hoyle M; Shepherd J; Armoiry X; Brazzelli M
    Appl Health Econ Health Policy; 2018 Aug; 16(4):429-432. PubMed ID: 29808296
    [No Abstract]   [Full Text] [Related]  

  • 20. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.